AZ and MSD's Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient

FDA grants fast review to BMS' first-line lung cancer combo

Bristol-Myers Squibb has finally made its bid for a slice of the lucrative first-line lung non-small cell lung cancer (NSCLC) market, after the FDA agreed to quickly review trial results fr

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

UK accounts for 12% of cell and gene therapy trials - report

The UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data published by a government-backed agency.

Clovis takes PARP prostate cancer pole position with fast FD...

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate cancer, the first drug in this class to target the indication.

NICE rejects Astellas' Xospata in AML, queries MSD's Keytrud...

NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's Keytruda in head and neck cancer